Genovis AB Stock: price and insider trades · Sweden

Headquartered in Lund, Sweden, Genovis AB belongs to the Healthcare & Pharma sector and traces its origins to 1999. Filings by its managers are published through Finansinspektionen. The last twelve months, up to 18 October 2026, brought 6 filings signed by 5 insiders.

The flow runs one way only: 5 insiders bought (6 purchases totalling €163k) and nobody sold on the market. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Those buying include 3 board members, 1 finance chief and 1 chief executive. One trade stands out by size: a purchase of €74k from Torben Jörgensen, disclosed on 1 October 2026, or 0.057% of market capitalisation.

Across the 890 companies tracked on its exchange, the median is 7 filings; at 6 filings, this issuer sits below that mark. Our records for Genovis AB go back to 2025, with 8 purchases and 2 sales on the open market in total.

In the case of 3 purchases, another manager of the company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last insider purchase was made public on 2 October 2026, 15 days ago. Most trades are made public on the day they happen. Under the Market Abuse Regulation, managers have three business days to notify their trades.

Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.